Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Guideline on Preventing VTE in Pediatric Cancer

J Thromb Haemost; ePub 2017 Nov 27; Tullius, et al

The International Society on Thrombosis and Hemostasis has released guidance on identifying at-risk patients and preventing venous thromboembolism in pediatric cancer. Among the recommendations:

  • Perform comprehensive risk assessment on each pediatric cancer patient at the initiation of cancer therapy.
  • Do not administer routine primary thromboprophylaxis in pediatric cancer patients without a history of prior thrombosis.
  • Administer thromboprophylaxis in pediatric cancer patients with prior thrombosis who are continuing to receive intensive therapy, as long as there are no anticoagulation contraindications.
  • Consider thromboprophylaxis on a case-by-case basis for pediatric cancer patients with no history of VTE, but with significant combinations of risk factors, including central venous catheters, asparaginase therapy, obesity, adolescence, hormonal contraceptives, or hospitalization for surgery.

Citation:

Tullius B, Athale U, van Ommen C, Chan A, Palumbo J, Balagtas J. The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: Guidance from the SSC of the ISTH. [Published online ahead of print November 27, 2017]. J Thromb Haemost. doi:10.1111/jth.13895.

This Week's Must Reads

FDA postmarketing requirements, Nabhan C et al. JAMA Oncol. 2018 May 10. doi:10.1001/jamaoncol.2018.0610.

Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.

Dapagliflozin suppresses hepcidin, Ghanim HA et al. AACE 2018, Abstract 228.

Methotrexate or nelarabine plus chemo in pediatric T-ALL or T-L, Dunsmore KP et al. ASCO 2018, Abstract 10500.

Blood type is diarrhea destiny, Kumar P et al. J Clin Invest. 2018 May 17; doi: 10.1172/JCI97659.

Must Reads in Bleeding Disorders

Reducing morbidity in postpartum hemorrhage, Smith R et al. Annual clinical and scientific meeting of the American Society of Obstetricians and Gynecologists 2018, Abstract 26R.

In sickle cell, start hydroxyurea in infancy, Schuchard S et al. ASPHO 2018, poster # 342 Schuchard S et al. ASPHO 2018, poster # 342. https://onlinelibrary.wiley.com/doi/10.1002/pbc.27057

Increase kidney function monitoring if INR exceeds 4.0, Traquair H et al. biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 79.

Vaccination lags in children with sickle cell disease, Wagner AL et al. J Pediatr. 2018 May;196:223-9.

Idarucizumab reversed dabigatran despite severe renal dysfunction, Eikelboom JW et al. ACC 18, the annual meeting of the American College of Cardiology, Abstract 1231M-11.